Tag Archives: Should

Should Macitentan Plus Riociguat Be Used as First-Line Therapy in PAH?

February 07, 2019 Share this content: Improvements in 6-minute walking distance scores and WHO functional class categories were seen in patients with PAH treated with macitentan plus riociguat. Upfront combination therapy with macitentan plus riociguat has demonstrated effectiveness in patients with pulmonary arterial hypertension (PAH), according to the results of a small retrospective, open-label cohort… Read More »

Healthcare? Gaming? Analysts Speculate on Where Apple Should Spend Its Cash – TheStreet.com

With Apple’s troublesome fourth quarter in the rearview mirror, investors are turning their attention to how the tech giant should spend its cash.  It’s time for Apple (AAPL) to go shopping, wrote analysts at JP Morgan in a note to clients on Monday. The iPhone maker has around $ 130 billion to its name in net cash, analyst… Read More »